Losartan onset
Pro Research Analysisby 
Searched over 200M research papers for "losartan onset"
Losartan Onset: Clinical Insights and Implications
Losartan and New-Onset Diabetes
Risk Reduction in Hypertensive Patients
Losartan, an angiotensin II receptor blocker (ARB), has been shown to significantly reduce the risk of new-onset diabetes in hypertensive patients. In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, hypertensive individuals treated with losartan exhibited a lower incidence of diabetes compared to those treated with atenolol, a beta-blocker. Specifically, new-onset diabetes occurred in 13.0 per 1000 person-years for losartan users versus 17.5 per 1000 person-years for atenolol users, indicating a relative risk reduction of 25% (relative risk 0.75, 95% confidence interval 0.63 to 0.88; P < 0.001). This suggests that losartan may offer protective benefits against the development of diabetes in patients with hypertension and left ventricular hypertrophy.
Losartan and Atrial Fibrillation
Prevention of New-Onset Atrial Fibrillation
The LIFE study also explored the effects of losartan on the incidence of new-onset atrial fibrillation (AF). Results indicated that losartan was more effective than atenolol in preventing new-onset AF. Over a follow-up period of approximately 4.8 years, new-onset AF occurred in 6.8 per 1000 person-years for losartan users compared to 10.1 per 1000 person-years for atenolol users, translating to a relative risk reduction of 33% (relative risk 0.67, 95% confidence interval 0.55 to 0.83; P < 0.001). This finding underscores the potential of losartan to maintain sinus rhythm and reduce the risk of AF-related complications, such as stroke and heart failure.
Losartan in COVID-19 Treatment
Efficacy in Symptomatic Outpatients
A recent multicenter phase II randomized clinical trial investigated the efficacy of losartan in symptomatic outpatients with COVID-19. The study aimed to determine whether losartan could mitigate the effects of the SARS-CoV-2 virus by modulating the renin-angiotensin-aldosterone system. However, the trial found no significant difference in the primary outcome of all-cause hospitalization between the losartan and placebo groups. Additionally, viral loads and adverse events were similar between the two groups, leading to the conclusion that losartan does not significantly impact the clinical course of mild symptomatic COVID-19 in low-risk outpatients.
Conclusion
Losartan demonstrates significant benefits in reducing the risk of new-onset diabetes and atrial fibrillation in hypertensive patients, making it a valuable option in managing these conditions. However, its efficacy in treating COVID-19 in symptomatic outpatients appears limited based on current evidence. These findings highlight the importance of context-specific application of losartan in clinical practice.
Sources and full results
Most relevant research papers on this topic